TORONTO, Oct. 1, 2024
In this free webinar, learn about the complex mechanisms of cancer drug resistance and how a four-step preclinical strategy can help identify effective tools to overcome it. Attendees will learn key models and approaches for targeting both intrinsic and acquired resistance phenotypes. Dr. Rajendra Kumari will share practical case studies demonstrating resistance to targeted therapies and immunotherapies.
Advertisement
TORONTO, Oct. 1, 2024 /PRNewswire-PRWeb/ -- Cancer drug resistance remains a significant hurdle in oncology, representing one of the greatest challenges in the development of effective cancer therapeutics. As resistance mechanisms evolve, they contribute to treatment failure and cancer-related mortality, underscoring the need for innovative solutions. The complexity of resistance � whether intrinsic or acquired � can be daunting and requires nuanced approaches for effective targeting and model development.
Advertisement
In this webinar, Dr. Rajendra Kumari will explore the evolving landscape of drug resistance and focus on innovative preclinical tools and strategies that can accelerate therapeutic discovery and provide actionable insights into overcoming resistance. She will also demonstrate how an integrated approach to early drug discovery can streamline the identification and development of new therapeutic strategies to counteract resistance.
Dr. Rajendra Kumari will also outline a robust four-step approach that can assist in identifying the most effective preclinical models to tackle both intrinsic and acquired resistance. This includes leveraging cutting-edge in vitro and in vivo models coupled with genetic engineering, imaging and multiomics advanced technologies designed to recapitulate resistance phenotypes and help identify resistance mechanisms early in the drug discovery process.
In this webinar, the attendees will gain insights into specific models that have been developed to study resistance to targeted therapies and immunotherapeutics. She will explore their key features, challenges and practical applications that can help in understanding how to utilize these models to predict clinical outcomes more effectively.
Register for this webinar today to explore the landscape of cancer drug resistance and learn how innovative preclinical tools and strategies can accelerate the discovery of cancer therapies.
Join Rajendra Kumari, PhD, Executive Director, Scientific Operations, Crown Bioscience, for the live webinar on Friday, October 18, 2024, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit Four-Step Preclinical Strategy to Tackle Cancer Drug Resistance.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com
View original content to download multimedia:https://www.prweb.com/releases/four-step-preclinical-strategy-to-tackle-cancer-drug-resistance-upcoming-webinar-hosted-by-xtalks-302263077.html
SOURCE Xtalks
